North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Haleon’s pilot run of the screener analyzed 1,500 pieces of creative for the Panadol pain relief brand across nine markets.

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

Syngene CFO Sibaji Biswas resigns, Deepak Jain to take over; Jayashree Aiyar appointed CSO, driving scientific strategy and ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

Nigeria's decision this week to block Shell's $2.4 billion sale of its onshore assets has sent a negative signal to investors ...

A report out earlier this month stated that both RSV shots on the market (GSK makes another one) were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the ...